<DOC>
	<DOCNO>NCT00367718</DOCNO>
	<brief_summary>This study seek test Efficacy term rate disease response metastatic nasopharyngeal carcinoma standard dose velcade 1.3 mg/m2 give day 1,4,8 , 11 every 21 day schedule . The study use Simons 2 stage design enroll 15-25 patient . Secondary endpoint study include Pharmacokinetics , toxicity , EBV viral load molecular characterization EBV plasma .</brief_summary>
	<brief_title>Trial VELCADE Patients With Metastatic Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Biopsy proven nasopharyngeal carcinoma – WHO type 3 ( recurrence metastasis ) metastatic disease locally recurrent disease amendable curative therapy Patients must measurable disease least one ( total three prior line chemotherapy metastatic recurrent disease ) . This must include least 1 prior line platinumcontaining chemotherapy . An ECOG performance status 0–2 Absolute neutrophil count ( ANC ) ≥1500/mm3 Hemoglobin  8g/dl ( blood transfusion allow correct hemoglobin level ) . PLT ≥ 75,000/mm 3 Total bilirubin ≤ 2 x upper normal limit ( UNL ) Serum ALT ≤ 5 x UNL Serum creatinine ≤ 2 mg/dL Serum albumin ≥ 2.5 g/dL No known history brain leptomeningeal metastasis . ≥ 18 year age . Estimated life expectancy ≥ 24 week . For sexually active woman childbearing potential , negative pregnancy test within 21 day enrol trial . must able give informed write consent Patients least 1 3 previous line treatment metastatic recurrent NPC Prior BORTEZOMIB therapy Immunotherapy ≤ 4 week elapse prior study entry Biologic therapy ≤ 4 week elapse prior study entry Radiation therapy ≤ 4 week elapse prior study entry Major surgery , significant traumatic injury ≤3 week prior study entry Other concurrent chemotherapy , immunotherapy , radiotherapy , therapy supportive care consider investigational Evidence CNS involvement Presence &gt; grade 1 sensory peripheral neuropathy etiology OR grade 1 neuropathic pain etiology . Patients significant local symptom metastasis amenable radiotherapy History allergic reaction attribute compound similar chemical biologic composition BORTEZOMIB . History malignancy ≤ 3 year prior study entry , except adequately treat basal cell , squamous cell skin cancer cervical intraepithelial neoplasia . Uncontrolled intercurrent illness Patients pregnant breast feeding ( Sexually active men woman childbearing potential must use contraception course therapy within 3 month completion trial ) Participation another clinical trial involve therapeutic intervention within 4 week enrollment . Known history HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>